Discontinued — last reported Q3 '24
Agilent Technologies Life Sciences and Applied Markets — CapEx remained flat by 0.0% to $15.00M in Q3 2024 compared to the prior quarter. Year-over-year, this metric declined by 14.3%, from $17.50M to $15.00M. Over 2 years (FY 2022 to FY 2024), Life Sciences and Applied Markets — CapEx shows a downward trend with a -11.7% CAGR.
An increase suggests management is investing in capacity expansion or modernization, while a decrease may indicate a focus on cash preservation or a shift toward asset-light operations.
This metric represents the cash outflows used by the Life Sciences and Applied Markets segment to acquire, upgrade, and...
Peer companies in the life sciences and diagnostics sector typically report this as 'Capital Expenditures' or 'Property, Plant, and Equipment Additions' within their segment disclosures.
a_segment_life_sciences_and_applied_markets_capital_expenditures| FY'22 | FY'23 | FY'24 | |
|---|---|---|---|
| Value | $77.00M | $70.00M | $60.00M |
| YoY Change | — | -9.1% | -14.3% |